| 1. |
Mori K, Hatakeyama S, Enokida H, Miyake H, Kikuchi E, Nishiyama H, Ichikawa T, Kamai T, Kaji Y, Kume H, Kondo T, Matsuyama H, Masumori N, Kawauchi A, Takenaka A, Uemura H, Eto M, Nonomura N, Fujii Y, Hinotsu S, Ohyama C:, Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association., Int J Urol, Int J Urol 31 (3): 194-207, 2024, 2024.03. |
| 2. |
Takamatsu D, Kohashi K, Kiyozawa D, Kinoshita F, Ieiri K, Baba M, Eto M, Oda Y:, TFE3-immunopositive papillary renal cell carcinoma: A clinicopathological, immunohistochemical, and genetic study., Pathol Res Pract, Pathol Res Pract 242: 154313, 2023, 2023.02. |
| 3. |
Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY:, LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy., Future Oncol, Future Oncol 19 (2): 113-121, 2023, 2023.01. |
| 4. |
Nishimura K, Shiota M, Eto M, Satoh T, Stroupe A, Seo C, Uzumcu A, Ledesma DA:, Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer (nmCRPC) patients., Cancer Med, Cancer Med 12 (2): 1762-1778, 2023, 2023.01. |
| 5. |
Kawano T, Inokuchi J, Eto M, Murata M, Kang JH:, Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer., Cancers (Basel), Cancers (Basel) 14 (21): 5425, 2022, 2022.11. |
| 6. |
Eto M, Lee JL, Chang YH, Gao S, Singh M, Gurney H:, Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region., Asia Pac J Clin Oncol, Asia Pac J Clin Oncol 18 (5): e191-e203, 2022, 2022.10. |
| 7. |
Shiota M, Akamatsu S, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:, Androgen receptor mutations for precision medicine in prostate cancer., Endocr Relat Cancer, Endocr Relat Cancer 29 (10): R143-R155, 2022, 2022.08. |
| 8. |
Matsumoto T, Shiota M, Blas L, Eto M:, Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective., Cancer Manag Res, 2022.08. |
| 9. |
Blas L, Shiota M, Eto M:, Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data., Cancers (Basel), Cancers (Basel) 14 (17): 4161, 2022, 2022.08. |
| 10. |
Blas L, Shiota M, Eto M:, Current status and future perspective on the management of metastatic castration-sensitive prostate cancer., Cancer Treat Res Commun, Cancer Treat Res Commun 32: 100606, 2022, 2022.07. |
| 11. |
Kiyozawa D, Kohashi K, Takamatsu D, Iwasaki T, Shibata D, Tomonaga T, Tateishi Y, Eto M, Kinjo M, Nishiyama K, Taguchi K, Oshiro Y, Kuboyama Y, Furuya M, Oda Y:, Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma., Hum Pathol, Hum Pathol 124: 36-44, 2022, 2022.06. |
| 12. |
Shiota M, Endo S, Blas L, Fujimoto N, Eto M:, Steroidogenesis in castration-resistant prostate cancer., Urol Oncol, Urol Oncol 41 (5): 240-251, 2023, 2022.05. |
| 13. |
Shiota M, Blas L, Eto M:, Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy., Cancers (Basel), Cancers (Basel) 14 (11): 2696, 2022, 2022.05. |
| 14. |
Kawano T, Inokuchi J, Eto M, Murata M, Kang JH:, Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials., Pharmaceutics, Pharmaceutics 13 (11): 1748, 2021, 2021.10. |
| 15. |
Kobayashi T, Takeuchi A, Nishiyama H, Eto M:, Current status and future perspectives of immunotherapy against urothelial and kidney cancer., Jpn J Clin Oncol, Jpn J Clin Oncol 51 (10): 1481-1492, 2021, 2021.10. |
| 16. |
Shiota M, Akamatsu S, Narita S, Terada N, Fujimoto N, Eto M:, Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer., JMA J, JMA J 4 (2): 99-111, 2021, 2021.04. |
| 17. |
Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y:, Perioperative therapies for urological cancers., Jpn J Clin Oncol, Jpn J Clin Oncol 50 (4): 357-367, 2020, 2020.04. |
| 18. |
Kato K, Takeuchi A, Akashi K, Eto M:, Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application., Front Immunol, Front Immunol 10: 3138, 2020, 2020.01. |
| 19. |
Shiota M, Fujimoto N, Kashiwagi E, Eto M:, The Role of Nuclear Receptors in Prostate Cancer., Cells, Cells 8 (6): 602, 2019, 2019.06. |
| 20. |
Inokuchi J, Eto M:, Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma., Cancer Manag Res, Cancer Manag Res 11: 4519-4528, 2019, 2019.05. |
| 21. |
Takeuchi A, Kato K, Akashi K, Eto M:, Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy., Int J Urol, Int J Urol 25 (2): 112-120, 2018, 2018.02. |
